![A close-up of the periodic table of elements highlighting "CU copper"](https://www.uc.edu/news/articles/2024/01/n21221567/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1706051185346.jpg)
The Cancer Letter highlights UC kidney cancer research
The Cancer Letter highlighted the University of Cincinnati Cancer Center’s Maria Czyzyk-Krzeska's new NIH-funded research that will investigate how copper contributes to the advancement and recurrence of clear cell renal cell carcinoma (ccRCC).
Research has found that increased accumulation of copper is associated with worse outcomes for patients with ccRCC, the most common type of kidney cancer.
“That indicated to us that copper has a potential driving effect in tumor progression of clear cell renal cell carcinoma,” said Czyzyk-Krzeska, a University of Cincinnati Cancer Center researcher and professor in the Department of Cancer Biology in UC’s College of Medicine.
The study will seek to identify the mechanisms that allow ccRCC cells to take up more copper, copper’s metabolic effects on the tumor cells and whether any of the copper-specific features of the tumor cells have vulnerabilities that can open up new treatments for ccRCC.
“There are essentially two or three major lines of treatment for kidney cancer, but ultimately there’s always a group of tumors that are not responsive or recur” said Czyzyk-Krzeska. “We hope what we find is going to provide opportunities for new treatments.”
Read The Cancer Letter article.
Featured photo at top of periodic table highlighting copper. Photo/HT Ganzo/iStock.
Related Stories
The Cancer Letter highlights UC kidney cancer research
January 23, 2024
The Cancer Letter highlighted the University of Cincinnati Cancer Center’s Maria Czyzyk-Krzeska's new NIH-funded research that will investigate how copper contributes to the advancement and recurrence of clear cell renal cell carcinoma.
Making pancreatic cancer treatments more effective
February 7, 2023
The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
GEN News: Biomarker discovery to help predict breast cancer outcomes
September 7, 2022
GEN News highlighted recent University of Cincinnati and Cincinnati Children's Hospital Medical Center research on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments.
Local 12: Researcher working to help patients with tough-to-beat pancreatic cancer
February 8, 2023
Local 12 highlighted the University of Cincinnati's Andrew Waters and his research into novel treatments for pancreatic cancer.
Head and neck, breast cancer research highlights AACR abstracts
April 14, 2023
University of Cincinnati Cancer Center researchers will present more than a dozen abstracts at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19, including findings that could advance treatments for head and neck and breast cancers.
Laser Focus World highlights UC research that uses light to restore cell function
September 29, 2022
Laser Focus World's Photonics Hot List highlighted the recent work of the University of Cincinnati's Jiajie Diao, PhD, who published research demonstrating a technique that uses light to help naturally balance mitochondria within cells.
Medium highlights UC research of light as treatment for cancer
August 10, 2022
Medium featured the research of the University of Cincinnati's Jiajie Diao, PhD, who recently published a paper showing early results that light-activated proteins can help normalize dysfunction within cells.
Local 12 highlights Pancreatic Cancer Awareness Month
November 27, 2023
Local 12 recently spoke with the University of Cincinnati's Andrew Waters and Pancreatic Cancer Action Network volunteers to discuss ongoing pancreatic cancer research and funding support during Pancreatic Cancer Awareness Month.
Unlocking the mysteries of cell migration
June 6, 2022
The University of Cincinnati's Atsuo Sasaki and an international team of collaborators have been awarded a Human Frontier Science Program research grant to learn more about how cells migrate, with an ultimate goal of developing new treatments to prevent cancer growth and spread.
Fierce Biotech: Making 'cold' tumors responsive to immunotherapy
June 25, 2020
Fierce Biotech highlights a study by UC researchers which lays the foundation for using a combination immunotherapy in breast cancer.